Prospects for the therapeutic development of umbilical cord bloodderived mesenchymal stem cells  

作　　者：Soyoun Um Jueun Ha Soo Jin Choi Wonil Oh Hye Jin Jin 

机构地区：[1]Research Team for Immune Cell Therapy,Biomedical Research Institute,MEDIPOST Co.,Ltd.,Seongnam 13494,South Korea [2]Research Team for Osteoarthritis,Biomedical Research Institute,MEDIPOST Co.,Ltd.,Seongnam 13494,South Korea [3]Biomedical Research Institute,MEDIPOST Co.,Ltd.,Seongnam 13494,South Korea

出　　处：《World Journal of Stem Cells》2020年第12期1511-1528,共18页世界干细胞杂志（英文版）（电子版）

摘　　要：Umbilical cord blood(UCB)is a primitive and abundant source of mesenchymal stem cells(MSCs).UCB-derived MSCs have a broad and efficient therapeutic capacity to treat various diseases and disorders.Despite the high latent selfrenewal and differentiation capacity of these cells,the safety,efficacy,and yield of MSCs expanded for ex vivo clinical applications remains a concern.However,immunomodulatory effects have emerged in various disease models,exhibiting specific mechanisms of action,such as cell migration and homing,angiogenesis,anti-apoptosis,proliferation,anti-cancer,anti-fibrosis,anti-inflammation and tissue regeneration.Herein,we review the current literature pertaining to the UCB-derived MSC application as potential treatment strategies,and discuss the concerns regarding the safety and mass production issues in future applications.

关 键 词：Umbilical cord blood Mesenchymal stem cell Stem cell therapy IMMUNOMODULATION Regenerative medicine Therapeutic cell manufacturing processing 

分 类 号：R457[医药卫生—治疗学]